524606 BERLDRG

Beryl Drugs Share Price

 

 

Start SIP in BERLDRG

Start SIP

Performance

  • Low
  • ₹22
  • High
  • ₹23
  • 52 Week Low
  • ₹17
  • 52 Week High
  • ₹43
  • Open Price₹22
  • Previous Close₹23
  • Volume617
  • 50 DMA₹22.85
  • 100 DMA₹22.87
  • 200 DMA₹23.78

Investment Returns

  • Over 1 Month -1.39%
  • Over 3 Month -3.23%
  • Over 6 Month + 5.03%
  • Over 1 Year -36.39%

Smart Investing Starts Here Start SIP with Beryl Drugs for Steady Growth!

Invest Now

Beryl Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49.3
  • PEG Ratio
  • -1.6
  • Market Cap Cr
  • 12
  • P/B Ratio
  • 1.2
  • Average True Range
  • 1.1
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.01
  • RSI
  • 49.43
  • MFI
  • 53.07

Beryl Drugs Financials

Beryl Drugs Technicals

EMA & SMA

Current Price
₹22.74
+ 0.11 (0.49%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹22.81
  • 50 Day
  • ₹22.85
  • 100 Day
  • ₹22.87
  • 200 Day
  • ₹23.78

Resistance and Support

22.5 Pivot Speed
  • R3 23.73
  • R2 23.24
  • R1 22.99
  • S1 22.25
  • S2 21.76
  • S3 21.51

Beryl Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-03 Others
2025-11-13 Quarterly Results
2025-09-02 A.G.M.
2025-08-07 Quarterly Results
2025-05-30 Audited Results

Beryl Drugs F&O

Beryl Drugs Shareholding Pattern

26.38%
66.25%
7.37%

About Beryl Drugs

  • NSE Symbol
  • BERLDRG
  • BSE Symbol
  • 524606
  • Managing Director
  • Mr. Sanjay Sethi
  • ISIN
  • INE415H01017

Similar Stocks to Beryl Drugs

Beryl Drugs FAQs

Beryl Drugs share price is ₹22 As on 12 January, 2026 | 06:33

The Market Cap of Beryl Drugs is ₹11.5 Cr As on 12 January, 2026 | 06:33

The P/E ratio of Beryl Drugs is 49.3 As on 12 January, 2026 | 06:33

The PB ratio of Beryl Drugs is 1.2 As on 12 January, 2026 | 06:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23